Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels

被引:256
|
作者
Bhasin, S
Storer, TW
Javanbakht, M
Berman, N
Yarasheski, KE
Phillips, J
Dike, M
Sinha-Hikim, I
Shen, RQ
Hays, RD
Beall, G
机构
[1] Charles R Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA
[2] Univ Calif Los Angeles, Dept Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pediat, Torrance, CA 90509 USA
[4] Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Radiol, Torrance, CA 90509 USA
[5] Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Med, Torrance, CA 90509 USA
[6] El Camino Coll, Lab Exercise Sci, Torrance, CA USA
[7] Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO USA
来源
关键词
D O I
10.1001/jama.283.6.763
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Previous studies of testosterone supplementation in HIV-infected men failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infected men are unknown. Objective To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infected men with low testosterone levels and weight loss. Design and Setting Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center. Participants Sixty-one HIV-infected men aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study. Interventions Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk intramuscularly), no exercise (n = 17); placebo and exercise (n = 15); or testosterone and exercise (n = 15). Treatment duration was 16 weeks. Main Outcome Measures Changes in muscle strength, body weight, thigh muscle volume, and lean body mass compared among the 4 treatment groups. Results Body weight increased significantly by 2.6 kg (P<.001) in men receiving testosterone alone and by 2.2 kg (P = .02) in men who exercised-alone but did not change in men receiving placebo alone (-0.5 kg; P = .55) or testosterone and exercise (0.7 kg; P = .08). Men treated with testosterone alone, exercise alone, or both experienced significant increases in maximum voluntary muscle strength in leg press (range, 22%-30%), leg curls (range, 18%-36%), bench press (range, 19%-33%), and latissimus pulls (range, 17%-33%). Gains in strength in all exercise categories were greater in men assigned to the testosterone-exercise group or to the exercise-alone group than in those assigned to the placebo-alone group. There was a greater increase in thigh muscle volume in men receiving testosterone alone (mean change, 40 cm(3); P<.001 vs zero change) or exercise alone (62 cm(3); P = .003) than in men receiving placebo alone (5 cm(3); P = .70). Average lean body mass increased by 2.3 kg (P = .004) and 2.6 kg (P<.001), respectively, in men who received testosterone alone or testosterone and exercise but did not change in men receiving placebo alone (0.9 kg; P = .21). Hemoglobin levels increased in men receiving testosterone but not in those receiving placebo. Conclusion Our data suggest that testosterone and resistance exercise promote gains in body weight, muscle mass, muscle strength, and lean body mass in HIV-infected men with weight loss and low testosterone levels. Testosterone and exercise together did not produce greater gains than either intervention alone.
引用
收藏
页码:763 / 770
页数:8
相关论文
共 50 条
  • [1] Effects of testosterone replacement and resistance exercise on body composition and muscle strength in HIV-infected men with weight loss and low testosterone levels.
    Bhasin, S
    Storer, TW
    Javanbakht, M
    Sinha-Hikim, I
    Shen, R
    Beall, G
    Berman, N
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 22A - 22A
  • [2] Characteristics of HIV-infected men with low serum testosterone levels
    Kopicko, JJ
    Momodu, I
    Adedokun, A
    Hoffman, M
    Clark, RA
    Kissinger, P
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 1999, 10 (12) : 817 - 820
  • [3] Testosterone replacement treatment options for HIV-infected men
    Cofrancesco, J
    Whalen, JJ
    Dobs, AS
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 16 (04) : 254 - 265
  • [4] Testosterone replacement therapy for bone loss prevention in HIV-infected males
    Clay, PG
    Lam, AI
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (04) : 582 - 585
  • [5] Testosterone replacement therapy and polycythemia in HIV-infected patients
    Vorkas, Charles Kyriakos
    Vaamonde, Carlos M.
    Glesby, Marshall J.
    [J]. AIDS, 2012, 26 (02) : 243 - 245
  • [6] Free Testosterone for Hypogonadism Assessment in HIV-Infected Men
    Monroe, Anne K.
    Brown, Todd T.
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 58 (11) : 1640 - 1640
  • [7] Low free testosterone in HIV-infected men is not associated with subclinical cardiovascular disease
    Monroe, A. K.
    Dobs, A. S.
    Xu, X.
    Palella, F. J.
    Kingsley, L. A.
    Post, W. S.
    Witt, M. D.
    Brown, T. T.
    [J]. HIV MEDICINE, 2012, 13 (06) : 358 - 366
  • [8] Free Testosterone for Hypogonadism Assessment in HIV-Infected Men Reply
    Danoff, A.
    Horberg, M.
    Aberg, J. A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 58 (11)
  • [9] Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems
    Bhatia, Ramona
    Murphy, Adam B.
    Raper, James L.
    Chamie, Gabriel
    Kitahata, Mari M.
    Drozd, Daniel R.
    Mayer, Kenneth
    Napravnik, Sonia
    Moore, Richard
    Achenbach, Chad
    [J]. AIDS, 2015, 29 (01) : 77 - 81
  • [10] Prospective study of topical testosterone gel (androgel) versus intramuscular testosterone in testosterone-deficient HIV-infected men
    Scott, James D.
    Wolfe, Peter R.
    Anderson, Peter
    Cohan, Gary R.
    Scarsella, Anthony
    [J]. HIV CLINICAL TRIALS, 2007, 8 (06): : 412 - 420